We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.
- Authors
Parikh, Ravi B.; Adamson, Blythe J. S.; Khozin, Sean; Galsky, Matthew D.; Baxi, Shrujal S.; Cohen, Aaron; Mamtani, Ronac
- Abstract
This research letter discusses the association between label restrictions by the US Food and Drug Administration on first-line immunotherapy for advanced bladder cancer and subsequent changes in practice.
- Subjects
UNITED States; UNITED States. Food &; Drug Administration; BLADDER cancer treatment; IMMUNOTHERAPY; CISPLATIN; ANTINEOPLASTIC agents; THERAPEUTIC use of monoclonal antibodies; ANTIGENS; BLADDER tumors; DRUG labeling; GOVERNMENT regulation
- Publication
JAMA: Journal of the American Medical Association, 2019, Vol 322, Issue 12, p1209
- ISSN
0098-7484
- Publication type
journal article
- DOI
10.1001/jama.2019.10650